Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | ctDNA sensitivity in early-stage disease

Bruna Pellini, MD, Moffitt Cancer Center, Tampa, FL, discusses remaining challenges in implementing circulating tumor DNA (ctDNA)-based approaches in clinical practice, highlighting difficulties in detecting early-stage disease which may result in false negatives. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.